Key result
Vildagliptin significantly improved left-ventricular contractile efficiency and attenuated cardiac hypertrophy in pressure-overloaded mice by inducing FGF21 expression via Sirt1.
Why the study?
To investigate the cardioprotective effect of the DPP-4 inhibitor vildagliptin on myocardial metabolism and cardiac performance under pressure overload.
Does vildagliptin improve cardiac function and myocardial energy metabolism in a murine model of pressure overload?
Does vildagliptin improve cardiac function and myocardial energy metabolism in a murine model of pressure overload?
Absolute Event Rate: 85.1% vs 77.3%
p-value: p=<0.05
Vildagliptin attenuates cardiac hypertrophy and improves contractile efficiency in pressure-overloaded hearts by inducing FGF21 expression in cardiac fibroblasts via Sirt1 signaling.
No immediate clinical implications for DPP-4 inhibitors in heart failure; leaves open potential benefits in pressure-overload states pending human data.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used incretin-based therapy for the treatment of type 2 diabetes. We investigated the cardioprotective effect of a DPP-4 inhibitor, vildagliptin (vilda), on myocardial metabolism and cardiac performance under pressure overload. Mice were treated with either vehicle or vilda, followed by transverse aortic constriction (TAC). After 3 weeks of TAC, cardiac hypertrophy and impairment of systolic function were attenuated in vilda-treated mice. Pressure-volume analysis showed that vilda treatment significantly improved left-ventricular contractile efficiency in TAC heart. Myocardial energy substrate analysis showed that vilda treatment significantly increased glucose uptake as well as fatty acid uptake. Fibroblast growth factor 21 (FGF21), a peptide involved in the regulation of energy metabolism, increased in TAC heart and was further increased by vilda treatment. FGF21 was strongly expressed in cardiac fibroblasts than in cardiomyocytes in mouse heart after TAC with vilda treatment. Vilda treatment markedly induced FGF21 expression in human cardiac fibroblasts through a sirtuin (Sirt) 1-mediated pathway, suggesting that fibroblast-mediated FGF21 expression may regulate energy metabolism and exert vilda-mediated beneficial effects in stressed heart. Vilda induced a metabolic regulator, FGF21 expression in cardiac fibroblasts via Sirt1, and increased contractile efficiency in murine pressure-overloaded heart.
No takes yet. Share an insight, caveat, or question.
Furukawa et al. (2020) studied Pressure overload-induced cardiac hypertrophy (n=31). Vildagliptin vs. Vehicle was evaluated on Left-ventricular contractile efficiency (%) (p=<0.05). Vildagliptin significantly improved left-ventricular contractile efficiency and attenuated cardiac hypertrophy in pressure-overloaded mice by inducing FGF21 expression via Sirt1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: